TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7527591

Group type: EXPERIMENTAL
Intervention: Cisplatin/5-FU chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin/5-FU) with radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin alone or combined with 5-FU with simultaneous radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard radiotherapy alone
Number of subjects: 0
Study: 2691278

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 micrograms b.i.d.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31441407

Group type: COMPARATOR
Intervention: Recombinant human high mobility group box 1 (rhHMGB1) treatment group (100 μg/L rhHMGB1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: UFH pretreatment group (10 kU/L UFH + 100 μg/L rhHMGB1)
Number of subjects: 4

Group type: COMPARATOR
Intervention: PBS control group (200 μL PBS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: UFH control group (10 kU/L UFH)
Number of subjects: 4
Study: 28521796

Group type: EXPERIMENTAL
Intervention: Follow-up supported by periodic phone calls by a nurse (intervention group) plus primary care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine primary care only (control group)
Number of subjects: 0
Study: 25520366

Group type: EXPERIMENTAL
Intervention: Zinc-fortified oral rehydration solution (3 mg Zn)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without Zn-fortified ORS)
Number of subjects: 0
Study: 22845710

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) pramipexole to extended-release (ER) pramipexole
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Extended-release (ER) pramipexole
Number of subjects: 228
Study: 21502384

Group type: EXPERIMENTAL
Intervention: QISS nonenhanced MR angiography
Number of subjects: 53

Group type: COMPARATOR
Intervention: Contrast-enhanced MR angiography and digital subtraction angiography
Number of subjects: 53
Study: 20175433

Group type: EXPERIMENTAL
Intervention: Honey-sweetened beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Commercial sports drink
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16428555

Group type: EXPERIMENTAL
Intervention: OLEH information system
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no OLEH)
Number of subjects: 2
Study: 15556261

Group type: EXPERIMENTAL
Intervention: Experimental group received croissants and magdalenas enriched with sterol esters, alpha‐tocopherol and beta‐carotene
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group received standard croissants and muffins
Number of subjects: 57
Study: 11426364

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (5 g)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 300
Study: 9438895

Group type: EXPERIMENTAL
Intervention: Granisetron 0.1 mg
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Granisetron 1.0 mg
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Granisetron 3.0 mg
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 8511243

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (three group educational sessions on HIV risk and protective behaviors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-only intervention
Number of subjects: 0
Study: 2948754

Group type: EXPERIMENTAL
Intervention: Low sodium intake (10 mmol/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Normal sodium intake (150 mmol/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High sodium intake (350 mmol/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Increasing sodium intake (from low to high)
Number of subjects: 11
Study: 31203512

Group type: EXPERIMENTAL
Intervention: Telephonic psycho-educational intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 29230568

Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group
Number of subjects: 1458

Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (transfemoral approach)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (transfemoral approach)
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (alternative approach)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (alternative approach)
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (within 30 days)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (within 30 days)
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (between 31 days and 2 years)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (between 31 days and 2 years)
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (in-hospital vascular complications)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (in-hospital vascular complications)
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: ABI < 0.9 group (acute kidney injury)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: ABI ≥ 0.9 group (acute kidney injury)
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: ABI < 0.9
Number of subjects: 1458
Study: 26453066

Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion controlling glycemia at 4.5‐7.2 mmol/l (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin administered in three doses controlling glycemia at 7.2‐10.0 mmol/l (Group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (Group C) without disturbances in carbohydrate metabolism
Number of subjects: 24
Study: 24277510

Group type: EXPERIMENTAL
Intervention: Percutaneous laser ablation (PLA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Radiofrequency thermoablation (RFA)
Number of subjects: 30
Study: 22314814

Group type: EXPERIMENTAL
Intervention: Subcutaneous allergen-specific immunotherapy (SCIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Topical treatment
Number of subjects: 64
Study: 20389151

Group type: COMPARATOR
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand (meta-analysis)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks (meta-analysis)
Number of subjects: 70
Study: 16920140

Group type: EXPERIMENTAL
Intervention: Coronary slow flow (CSF) patients (group I)
Number of subjects: 48
Study: 15724103

Group type: EXPERIMENTAL
Intervention: 0.1% retinaldehyde/6% glycolic acid (Diacneal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 12006897

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10187944

Group type: EXPERIMENTAL
Intervention: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 560 mg over 12 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 715 mg over 20 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined steroid therapy
Number of subjects: 20
Study: 7738344

Group type: EXPERIMENTAL
Intervention: Lugol's solution (approximately 170 ppm free molecular iodine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level povidone-iodine preparations (0.5-20 ppm free iodine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial povidone-iodine preparation
Number of subjects: 0
Study: 2262896

Group type: EXPERIMENTAL
Intervention: Caffeine withdrawal (100 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (substituted for caffeine)
Number of subjects: 7
Study: 6968819

Group type: EXPERIMENTAL
Intervention: Chronic electrical stimulation of the cerebellum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chronic electrical stimulation of the cerebellum (on stimulation)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Chronic electrical stimulation of the cerebellum (off stimulation)
Number of subjects: 14
Study: 30888265

Group type: EXPERIMENTAL
Intervention: Chlorine disinfection (Aquatabs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flocculent disinfection (Procter and Gamble Purifier of Water [P&G PoW])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceramic Filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard SAM treatment protocol
Number of subjects: 0
Study: 29084313

Group type: EXPERIMENTAL
Intervention: Unilateral FUS thalamotomy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 27
Study: 24433223

Group type: EXPERIMENTAL
Intervention: diclofenac+heparin
Number of subjects: 104

Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 104

Group type: COMPARATOR
Intervention: heparin
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study: 23939867

Group type: EXPERIMENTAL
Intervention: Lidocaine (1% lidocaine)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 21063131

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg/day
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg/day
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg/day
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg/day (week 2)
Number of subjects: 154
Study: 19101255

Group type: EXPERIMENTAL
Intervention: Proficiency-based laparoscopic suturing simulator training
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intertraining intervals (1 to 43 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Shorter intertraining intervals
Number of subjects: 66
Study: 17322624

Group type: EXPERIMENTAL
Intervention: Flecainide 25 mg BID
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Flecainide 50 mg BID
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg BID
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 15985570

Group type: EXPERIMENTAL
Intervention: PSP patients (n=21)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal control subjects (n=31)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PD patients (n=23)
Number of subjects: 100

Group type: COMPARATOR
Intervention: MSA-P patients (n=25)
Number of subjects: 100
Study: 12574046

Group type: EXPERIMENTAL
Intervention: Computerised clinical decision support system
Number of subjects: 53
Study: 10563031

Group type: EXPERIMENTAL
Intervention: Methadone (33% increase in daily dosage)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8690830

Group type: EXPERIMENTAL
Intervention: Zolpidem (5, 10, and 20 mg/70 kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25, and 0.50 mg/70 kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Temazepam (15, 30, and 60 mg/70 kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1988895

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Upper genital tract isolates (Group B streptococcus, Enterococcus faecalis)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Upper genital tract isolates (Enterococcus faecalis)
Number of subjects: 102
Study: 6122099

Group type: EXPERIMENTAL
Intervention: GL enzyme (hyaluronidase)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 30782952

Group type: EXPERIMENTAL
Intervention: Internet-based neck-specific exercises (NSE) for 3 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Prescribed physical activity (PPA) for 3 months
Number of subjects: 140
Study: 28436479

Group type: EXPERIMENTAL
Intervention: NP/NC with additional TCM (n=156)
Number of subjects: 314

Group type: COMPARATOR
Intervention: NP/NC (control, n=158)
Number of subjects: 314
Study: 27629730

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin + 10 mg ezetimibe therapy for 6 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 24886536

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo mouthrinse for 4 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (CHX and placebo)
Number of subjects: 50
Study: 21933330

Group type: EXPERIMENTAL
Intervention: Metformin and lifestyle intervention (low glycaemic index diet and exercise programme)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (ADT alone)
Number of subjects: 40
Study: 19222309

Group type: EXPERIMENTAL
Intervention: Attention training condition (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control dot-probe task condition (n = 18)
Number of subjects: 36
Study: 17997224

Group type: EXPERIMENTAL
Intervention: Sativex (oro‐mucosal THC: CBD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 125
Study: 16025924

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11925283

Group type: EXPERIMENTAL
Intervention: Ondansetron 20 microg/day
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ondansetron 100 microg/day
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 9419299

Group type: EXPERIMENTAL
Intervention: Laparoscopic intraoperative ultrasonography (LIOU)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Dynamic intraoperative cholangiography (IOC)
Number of subjects: 518
Study: 7611266

Group type: EXPERIMENTAL
Intervention: Intravenous iron dextran (100 mg twice weekly)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Oral iron therapy
Number of subjects: 52
Study: 2171050

Group type: EXPERIMENTAL
Intervention: Doppler US
Number of subjects: 14

Group type: COMPARATOR
Intervention: Digital angiography
Number of subjects: 14
Study: 380915

Group type: EXPERIMENTAL
Intervention: Amineptine (200 mg per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amitriptyline (75 mg per day)
Number of subjects: 51
Study: 30683146

Group type: EXPERIMENTAL
Intervention: 1% simvastatin-acid sodium salt ointment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1% atorvastatin calcium salt ointment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle ointment (control)
Number of subjects: 24
Study: 28454798

Group type: EXPERIMENTAL
Intervention: Valsartan 80 to 320 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26054142

Group type: EXPERIMENTAL
Intervention: Combined therapy of Zhuang medicine at Qineihuan point and conventional acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study: 24060346

Group type: EXPERIMENTAL
Intervention: L‐NMMA (an unspecific nitric oxide synthase inhibitor)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phenylephrine (an α‐adrenoceptor agonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20878646

Group type: EXPERIMENTAL
Intervention: Adjuvant treatments
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Fatigue and depression
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Body mass index and comorbidity
Number of subjects: 537
Study: 19684412

Group type: EXPERIMENTAL
Intervention: Rigorous volume management during thrice-weekly hemodialysis
Number of subjects: 22
Study: 17412579

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1500 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 8
Study: 15805763

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 0
Study: 11422135

Group type: EXPERIMENTAL
Intervention: Responses from three of the eight questions for adults
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Responses from two questions for children
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Overall model for both age groups
Number of subjects: 922
Study: 9631604

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine arterial separation with coagulation (Group 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Uterine artery coagulated by bipolar electrocoagulator through vaginal route (Group 2)
Number of subjects: 70
Study: 7946367

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (75 micrograms/hr)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Epidural fentanyl
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous (IV) fentanyl
Number of subjects: 54

Group type: COMPARATOR
Intervention: Transdermal fentanyl
Number of subjects: 54
Study: 3499244

Group type: EXPERIMENTAL
Intervention: Propofol (PROP), 2.5 mg . kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Thiopentone (THIO), 4 mg . kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Methohexitone (METH), 1.5 mg . kg‐1
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control values (baseline measurements)
Number of subjects: 180
Study: 31390087

Group type: EXPERIMENTAL
Intervention: Cigarette cue
Number of subjects: 102

Group type: COMPARATOR
Intervention: Water cue
Number of subjects: 102
Study: 28905874

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine transdermal patch (TNP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo transdermal patch (PBO)
Number of subjects: 80
Study: 28222525

Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention (CI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 25803648

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia to a temperature of 32-33°C for 72 hours
Number of subjects: 55

Group type: COMPARATOR
Intervention: Strict normothermia to a temperature of 36-37°C for 72 hours
Number of subjects: 55
Study: 23505907

Group type: EXPERIMENTAL
Intervention: Postconditioning (PC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 21383834

Group type: EXPERIMENTAL
Intervention: Tactile two-tap apparent-motion streams with an SOA of 400 ms, paired with auditory beeps at various SOAs (from -75 ms to 75 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile two-tap apparent-motion streams with a long SOA (325 ms) and a short SOA (75 ms), with both beeps occurring close to the taps on one side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile two-tap apparent-motion streams with only odd-numbered taps paired with auditory beeps
Number of subjects: 0
Study: 18815716

Group type: EXPERIMENTAL
Intervention: Blue-enriched white light (17 000 K)
Number of subjects: 94

Group type: COMPARATOR
Intervention: White light (4000 K)
Number of subjects: 94
Study: 16818281

Group type: EXPERIMENTAL
Intervention: CD34+‐selected peripheral blood cells (group C)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Unmanipulated marrow or blood cells (group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No further donor cell infusion (group A)
Number of subjects: 54
Study: 12621795

Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (rFSH) 100 IU
Number of subjects: 224

Group type: COMPARATOR
Intervention: Urinary follicle-stimulating hormone (uFSH) 150 IU
Number of subjects: 224
Study: 12757434

Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs) in health sciences librarianship
Number of subjects: 0
Study: 9457926

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (follitropin beta, Puregon)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Urinary FSH (urofollitropin, Metrodin)
Number of subjects: 172
Study: 8168027

Group type: EXPERIMENTAL
Intervention: Preoperative evaluation and postoperative care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for pre-existing disease
Number of subjects: 0
Study: 2679204

Group type: EXPERIMENTAL
Intervention: Specialized female unit (EWA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional mixed-sex alcoholism treatment centers
Number of subjects: 200
Study: 1053489

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 29378998

Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronic acid (Gengigel) applied in postextraction sockets of the right third molars
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no treatment applied to extraction sockets of the left third molars)
Number of subjects: 25
Study: 25497252

Group type: EXPERIMENTAL
Intervention: Intralesion abciximab and aspiration thrombectomy
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 452
Study: 23661523

Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids and arginine enhanced formula (3 cans per day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Omega 3 fatty acids and arginine enhanced formula (2 cans per day)
Number of subjects: 37
Study: 21205136

Group type: EXPERIMENTAL
Intervention: pegylated interferon (PEG‐IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: shorter treatment (12‐16 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: shorter treatment (12‐16 weeks) in subgroup with RVR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: prolonging therapy
Number of subjects: 0